CSIMarket Company Name, Ticker, Competitors, else..
 
Candel Therapeutics Inc   (NASDAQ: CADL)
 
Price: $6.4700 $0.67 11.552%
Day's High: $6.825 Week Perf: 21.39 %
Day's Low: $ 5.72 30 Day Perf: 28.88 %
Volume (M): 3,505 52 Wk High: $ 13.68
Volume (M$): $ 22,675 52 Wk Avg: $6.22
Open: $5.72 52 Wk Low: $4.25



 Market Capitalization (Millions $) 355
 Shares Outstanding (Millions) 55
 Employees 38
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) 70
 Capital Exp. (TTM) (Millions $) 0

Candel Therapeutics Inc
Candel Therapeutics Inc is a clinical-stage biotechnology company that focuses on the development of novel oncolytic viral immunotherapies for the treatment of certain types of cancer. Using their proprietary CANDEL platform, the company engineers viruses to selectively target and destroy cancer cells while activating the immune system to mount an anti-tumor response. Their goal is to develop safe and effective treatments that can improve patient outcomes and potentially provide long-term remission in various cancers.


   Company Address: 117 Kendrick St Needham 2494 MA
   Company Phone Number: 916-5445   Stock Exchange / Ticker: NASDAQ CADL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.79%    
EXEL   -6.7%    
IOVA        2.27% 
IVVD        6.73% 
MRNA        6.97% 
NVAX   -3.18%    
• View Complete Report
   



Clinical Study

Candel Therapeutics Advances Cancer Immunotherapy Frontier with Landmark Trials in Glioblastoma and Prostate Cancer,...

Published Tue, Oct 14 2025 3:50 PM UTC

Candel Therapeutics: A Trailblazer in Cancer Immunotherapy with Promising Outcomes in Glioblastoma and Prostate CancerCandel Therapeutics, Inc. (Nasdaq: CADL), a pioneering clinical-stage biopharmaceutical company, continues to make significant strides in the realm of cancer immunotherapy. Building upon its evolving portfolio of multimodal biological therapies designed to h...
Management Changes

Candel Therapeutics Taps Pancreatic Cancer Authority Elizabeth Jaffee Amid Financial Struggles: Searching for Breakthroughs in a Challenging Landscape,

Published Tue, Mar 18 2025 12:02 PM UTC

Candel Therapeutics Appoints Pancreatic Cancer Expert Amid Struggles: A New Chapter or an Uphill Battle?NEEDHAM, Mass.?In a move that signals both promise and urgency, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company, has appointed Dr. Elizabeth M. Jaffee, an internationally renowned expert in cancer immunology and pancreatic cancer, to i...
Clinical Study

Candel Therapeutics? CAN-2409 A New Dawn in Prostate Cancer Immunotherapy with Promising Phase 3 Trial Results

Published Mon, Dec 30 2024 2:16 AM UTC

Candel Therapeutics, a clinical-stage biopharmaceutical company, has made significant strides in the fight against cancer with the recent announcement of their Phase 3 trial results for CAN-2409, a novel viral immunotherapy designed to treat localized prostate cancer. This milestone not only marks a pivotal moment for the company but also potentially reshapes the therapeutic...
Shares

Candel Therapeutics Expands Financial Base with Strategic Public Offering Amidst Promising Immunotherapy Developments

Published Fri, Dec 13 2024 4:01 AM UTC

Candel Therapeutics, Inc. a clinical-stage biopharmaceutical company based in Needham, Massachusetts, continues to make strides in the fight against cancer. On December 12, 2024, the company announced the pricing of an underwritten public offering aimed at bolstering its financial position, which comes on the heels of noteworthy advancements in their immunotherapy pipeline...
Clinical Study

Promising Advances in Cancer Treatments Candel Therapeutics Immunotherapy Pipeline Thrives with CAN-3110 and CAN-2409

Published Tue, Nov 5 2024 2:01 PM UTC

Candel Therapeutics, Inc. a clinical-stage biopharmaceutical company, has made significant strides in the development of its multimodal biological immunotherapies for cancer treatment. Recent announcements about preclinical data for CAN-3110 in melanoma and convincing phase 2 results for CAN-2409 in non-small cell lung cancer (NSCLC) suggest a bright future for both compoun...









Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.